FORMER MSD Australia MD Will Delaat has died, just six weeks after he resigned as a Director of ASX-listed Pharmaxis Limited.
Delaat was head of MSD for 11 years prior to his retirement in 2008, with his extensive industry career also seeing him serve two terms as Chair of industry peak body Medicines Australia (MA), with the organisation's current CEO, Elizabeth de Somer, paying tribute to his contribution.
"Will Delaat championed big thinking and passion for bringing innovative medicines to Australia, and his well-respected leadership greatly benefited Australia's health system and the patients that rely on it," she said.
As well as roles with MSD in Australia and Europe, Delaat also worked with AstraZeneca, with colleagues hailing his ability to bring people together.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Sep 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Sep 22
